Jinyu Bio-technology (600201) Stock Overview
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
600201 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Jinyu Bio-technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.95 |
| 52 Week High | CN¥19.00 |
| 52 Week Low | CN¥6.50 |
| Beta | 0.92 |
| 1 Month Change | -4.29% |
| 3 Month Change | 3.89% |
| 1 Year Change | 110.86% |
| 3 Year Change | 29.10% |
| 5 Year Change | -25.84% |
| Change since IPO | 1,221.63% |
Recent News & Updates
Recent updates
The Consensus EPS Estimates For Jinyu Bio-technology Co., Ltd. (SHSE:600201) Just Fell Dramatically
Sep 04
Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Sep 02Why We're Not Concerned Yet About Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) 25% Share Price Plunge
Jun 16Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Are Reducing Their Forecasts For This Year
Apr 30There's Reason For Concern Over Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Price
Mar 21Does This Valuation Of Jinyu Bio-technology Co., Ltd. (SHSE:600201) Imply Investors Are Overpaying?
Feb 28Shareholder Returns
| 600201 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -6.7% | -2.8% | -2.4% |
| 1Y | 110.9% | -0.5% | 26.2% |
Return vs Industry: 600201 exceeded the CN Biotechs industry which returned -0.5% over the past year.
Return vs Market: 600201 exceeded the CN Market which returned 26.2% over the past year.
Price Volatility
| 600201 volatility | |
|---|---|
| 600201 Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 600201's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 600201's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,740 | Jing Zhang | www.jinyu.com.cn |
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines.
Jinyu Bio-technology Co., Ltd. Fundamentals Summary
| 600201 fundamental statistics | |
|---|---|
| Market cap | CN¥16.34b |
| Earnings (TTM) | CN¥100.76m |
| Revenue (TTM) | CN¥1.33b |
Is 600201 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600201 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.33b |
| Cost of Revenue | CN¥652.67m |
| Gross Profit | CN¥674.39m |
| Other Expenses | CN¥573.63m |
| Earnings | CN¥100.76m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | 0.092 |
| Gross Margin | 50.82% |
| Net Profit Margin | 7.59% |
| Debt/Equity Ratio | 0.3% |
How did 600201 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/08 10:28 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jinyu Bio-technology Co., Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Siyang Wang | China International Capital Corporation Limited |
| Xia Sheng | Citic Securities Co., Ltd. |